B7-1 (CD80), FC Fusion, Biotin Labeled
SIGMA/SRP0526 - recombinant, expressed in HEK 293 cells
Synonym: CTLA-4 Counter-Receptor B7.1
Product Type: Chemical
| form | frozen liquid |
| mol wt | 52.5 kDa |
| recombinant | expressed in HEK 293 cells |
| shipped in | dry ice |
| storage temp. | −70°C |
| UniProt accession no. | P33681 ![]() |
| Biochem/physiol Actions: | CD80 is an efficient costimulatory molecule essential for immune surveillance during carcinogenesis. It inhibits cancer progression. It regulates the T cell activation to control immune response. Cell stress increases the CD80 expression. Reduced expression of CD80 is observed in colon carcinoma. High levels of CD80 stimulate anti-tumor immune responses. Therefore, enhancing CD80 expression in tumors might serve as a potent approach for cancer immunotherapy. Urinary CD80 is recognized as an important biomarker for idiopathic nephrotic syndrome (INS). CD80 might be involved in proteinuria, actin reorganization, and podocyte migration. Its expression in podocytes is associated with minimal change disease (MCD). |
| General description: | CD80 or B7-1 is expressed in the antigen-presenting cells (APC). The CD80 gene is mapped to human chromosome 3q13.33. |
| General description: | Human secreted B7-1-Fc fusion protein, also known as CD80, with C-terminal Avitag™ . GenBank Accession No. NM_005191, a.a 35-242 expressed in a HEK293 cell expression system and enzymatically biotin-labeled using Avitag™ technology. MW = 52.5 kDa (monomer). This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. |
| Legal Information: | AviTag is a trademark of Avidity, LLC |
| Physical form: | Aqueous solution |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 |
| Precautionary statements | P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Storage Temp. | −70°C |
| UNSPSC | 12352202 |


